Stocktoria
Esperion Therapeutics, Inc. ESPR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-06-24
Esperion Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $403.1M | $332.3M | $116.3M | $75.5M | $78.4M |
| SG&A expense | $165.8M | $163.1M | $142.5M | $109.1M | $185.0M |
| Operating income | $60.3M | $54.4M | -$155.6M | -$179.5M | -$226.7M |
| Interest expense | — | — | $59.0M | $56.8M | $46.4M |
| Income tax | $1.8M | $0 | $0 | $0 | $0 |
| Net income | -$22.7M | -$51.7M | -$209.2M | -$233.7M | -$269.1M |
| EPS (diluted) | $-0.11 | $-0.28 | $-2.03 | $-3.52 | $-9.31 |
| Operating cash flow | -$13.1M | -$23.7M | -$135.5M | -$174.8M | -$263.8M |
| Free cash flow | -$13.1M | -$24.0M | -$135.5M | -$174.8M | -$263.8M |
| Cash & equivalents | $167.9M | $144.8M | $82.2M | $124.8M | $208.9M |
| Inventory | $105.1M | $94.5M | $65.6M | $35.2M | $34.4M |
| Total assets | $465.9M | $343.8M | $205.8M | $247.9M | $381.6M |
| Total liabilities | $767.9M | $732.5M | $660.8M | $571.7M | $578.5M |
| Shareholders' equity | -$302.0M | -$388.7M | -$455.0M | -$323.8M | -$196.9M |
Source: SEC EDGAR filings · CIK 0001434868 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.